Motley Fool Wealth Management LLC Has $1.06 Million Holdings in Kenvue Inc. $KVUE

Motley Fool Wealth Management LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 12.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,387 shares of the company’s stock after selling 7,231 shares during the period. Motley Fool Wealth Management LLC’s holdings in Kenvue were worth $1,055,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Evergreen Wealth Solutions LLC grew its stake in shares of Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after acquiring an additional 432 shares in the last quarter. Wealth Alliance LLC grew its stake in shares of Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock valued at $762,000 after acquiring an additional 486 shares in the last quarter. Everett Harris & Co. CA lifted its position in Kenvue by 1.4% during the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock worth $887,000 after purchasing an additional 500 shares during the period. Proffitt & Goodson Inc. lifted its position in Kenvue by 8.2% during the second quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock worth $143,000 after purchasing an additional 517 shares during the period. Finally, UMB Bank n.a. lifted its position in Kenvue by 22.3% during the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock worth $60,000 after purchasing an additional 521 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. UBS Group cut their price objective on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Citigroup cut their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research report on Friday, September 26th. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 price objective on shares of Kenvue in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.90.

Kenvue Stock Down 3.9%

KVUE stock opened at $14.49 on Wednesday. The stock has a market capitalization of $27.80 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 2.18 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $14.05 and a 12 month high of $25.17. The firm has a 50-day moving average price of $17.64 and a 200-day moving average price of $20.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.